ARL4C and hepatocellular carcinoma: Research has shown that ADP-ribosylation factor (ARF)-like 4c (Arl4c) expression is stimulated by the activation of the β-catenin or EGFR-MAP kinase pathways, contributing to tumourigenesis in various cancer types, including HCC.